Evidence map›Paper›PMID 34354042›Full record

ArticleCell death & disease2021

Precision genetic cellular models identify therapies protective against ER stress.

Irina V Lebedeva, Michelle V Wagner, Sunil Sahdeo, Yi-Fan Lu, Anuli Anyanwu-Ofili, Matthew B Harms, Jehangir S Wadia, Gunaretnam Rajagopal, Michael J Boland, David B Goldstein

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. AInternational journal of molecular sciences · 2022
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Irina V LebedevaInstitute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-1693-9392
Michelle V WagnerJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, CA, USA.
Sunil SahdeoJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, CA, USA.
Yi-Fan LuInstitute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Anuli Anyanwu-OfiliDiscovery Sciences, Janssen R&D, Spring House, PA, USA.
Matthew B HarmsDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Jehangir S WadiaJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, CA, USA.
Gunaretnam RajagopalDiscovery Sciences, Janssen R&D, Spring House, PA, USA.
Michael J BolandInstitute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA. mb4129@columbia.edu.ORCID 0000-0001-5649-9603
David B GoldsteinInstitute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA. dg2875@columbia.edu.
Columbia University Irving Medical Center · USJohnson & Johnson (United States) · USColumbia University · USJanssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare monogenic disorders often share molecular etiologies involved in the pathogenesis of common diseases. Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are rare pediatric disorders with symptoms that range from mild to life threatening. A biological mechanism shared among CDG and CDDG as well as more common neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis, is endoplasmic reticulum (ER) stress. We developed isogenic human cellular models of two types of CDG and the only known CDDG to discover drugs that can alleviate ER stress. Systematic phenotyping confirmed ER stress and identified elevated autophagy among other phenotypes in each model. We screened 1049 compounds and scored their ability to correct aberrant morphology in each model using an agnostic cell-painting assay based on >300 cellular features. This primary screen identified multiple compounds able to correct morphological phenotypes. Independent validation shows they also correct cellular phenotypes and alleviate each of the ER stress markers identified in each model. Many of the active compounds are associated with microtubule dynamics, which points to new therapeutic opportunities for both rare and more common disorders presenting with ER stress, such as Alzheimer's disease and amyotrophic lateral sclerosis.

Indexed as

Models, BiologicalActivating Transcription Factor 6ApoptosisAutophagyCell LineCell ProliferationCell ShapeCongenital Disorders of GlycosylationDrug Evaluation, PreclinicalEndoplasmic Reticulum StressHumansPhenotypeProtective AgentsReproducibility of ResultsX-Box Binding Protein 1Activating Transcription Factor 6ATF6 protein, humanProtective AgentsX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID34354042
PMCPMC8342410
OpenAlexW3187992478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.